Avarieux
back to explore
Amylyx Pharmaceuticals Inc logo

AMLX

Amylyx Pharmaceuticals Inc
NASDAQ NMS - GLOBAL MARKET· Pharmaceuticals· US· IPO 2022-01-07
$34.49
+0.68 (+2.01%)
last quote
Want the full multi-source brief on AMLX?
The agent pulls regulatory filings, news flow, prediction-market pricing, and macro context — then synthesizes what's not yet in the price.
open in agent
Today
Open
$34.49
High
$35.48
Low
$34.00
Previous close
$33.81
Fundamentals
Market cap
$2.50B
P/E (TTM)
—
P/S (TTM)
12.75x
P/B
4.35x
Gross margin
82.75%
Operating margin
-99.16%
Net margin
-94.56%
Rev growth (YoY)
—
EPS growth (YoY)
—
ROE
-52.92%
52W high
$41.14
52W low
$9.14
Beta
-0.11x
Industry peers
by market cap
AMRX+2.15%LGND+0.93%DFTX+1.04%EWTX-0.64%ELVN+1.99%INDV+1.42%MANE+0.97%TARS+11.76%
Upcoming earnings
next 30 days
2026-11-04in 61 days
Q3 2026EPS est $-0.39
Recent SEC filings
CIK 1658551filing-language history →
42026-09-02reports 2026-08-31
10 KB
42026-08-20reports 2026-08-18
10 KB
42026-08-20reports 2026-08-18
5 KB
42026-08-20reports 2026-08-18
5 KB
42026-08-20reports 2026-08-18
5 KB
42026-08-20reports 2026-08-18
5 KB
Recent news
2026-08-27 → 2026-09-03
Benzinga · 6d
Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $57
Guggenheim analyst Seamus Fernandez maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $55 to $57.
SEC EDGAR Yahoo Finance TradingView Company website
This is the free preview

The agent layer adds regulatory-language drift detection, cross-venue prediction-market signals, macro overlays, programmable alert rules, overnight briefs, and a grounding verifier on every claim. 7-day Pro trial, no card required.

Start the trial